General Information of Drug (ID: DMFSHXW)

Drug Name
example 8 [WO1999033801A1] Drug Info
Synonyms example 8 [WO1999033801A1]; GTPL8581
Indication
Disease Entry ICD 11 Status REF
Discovery agent N.A. Investigative [1]
Cross-matching ID
PubChem CID
57180216
TTD Drug ID
DMFSHXW

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Discontinued Drug(s)
Investigative Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
UCL-2000; butabindide DML51D0 Obesity 5B81 Discontinued in Phase 1 [3]
(2S)-aminobutyryl-L-proline-(2S)-methylbutylamide DMEWU6Z Discovery agent N.A. Investigative [4]
L-valyl-L-prolinamide DMH7TNA Discovery agent N.A. Investigative [4]
(2S)-aminobutyryl-L-proline n-butylamide DM12Q9O Discovery agent N.A. Investigative [4]
L-norvalyl-L-prolinamide DMIXFGC Discovery agent N.A. Investigative [4]
L-valyl-L-proline benzylamide DMQZ13A Discovery agent N.A. Investigative [4]
(2S)-aminobutyryl-L-prolinamide DMG0QKL Discovery agent N.A. Investigative [4]
peptide 4 DM45RTZ Discovery agent N.A. Investigative [5]
(2S)-aminobutyryl-(R)-pipecolinic acid amide DMWQK86 Discovery agent N.A. Investigative [4]
L-norleucyl-L-prolinamide DM7V30L Discovery agent N.A. Investigative [4]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Tripeptidyl-peptidase II (TPP2) TTQ7R2V TPP2_HUMAN Inhibitor [2]

References

1 Structure and function of tripeptidyl peptidase II, a giant cytosolic protease. Biochim Biophys Acta. 2012 Jan;1824(1):237-45.
2 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2423).
3 Emerging drugs for obesity: linking novel biological mechanisms to pharmaceutical pipelines. Expert Opin Emerg Drugs. 2005 Aug;10(3):643-60.
4 Inhibitors of tripeptidyl peptidase II. 3. Derivation of butabindide by successive structure optimizations leading to a potential general approach ... J Med Chem. 2005 Nov 17;48(23):7333-42.
5 Use of lantibiotic synthetases for the preparation of bioactive constrained peptides. Bioorg Med Chem Lett. 2008 May 15;18(10):3025-8.